Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Cancer is one of the most complicated diseases in present-day medical science. Yearly, several studies suggest various strategies for preventing carcinogenesis. Furthermore, experiments for the treatment of cancer with low side effects are ongoing. Chemotherapy, targeted therapy, radiotherapy and immunotherapy are the most common non-invasive strategies for cancer treatment. One of the most challenging issues encountered with these modalities is low effectiveness, as well as normal tissue toxicity for chemo-radiation therapy. The use of some agents as adjuvants has been suggested to improve tumor responses and also alleviate normal tissue toxicity. Resveratrol, a natural flavonoid, has attracted a lot of attention for the management of both tumor and normal tissue responses to various modalities of cancer therapy. As an antioxidant and anti-inflammatory agent, in vitro and in vivo studies show that it is able to mitigate chemo-radiation toxicity in normal tissues. However, clinical studies to confirm the usage of resveratrol as a chemo-radioprotector are lacking. In addition, it can sensitize various types of cancer cells to both chemotherapy drugs and radiation. In recent years, some clinical studies suggested that resveratrol may have an effect on inducing cancer cell killing. Yet, clinical translation of resveratrol has not yielded desirable results for the combination of resveratrol with radiotherapy, targeted therapy or immunotherapy. In this paper, we review the potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 20(2020), 2 vom: 18., Seite 130-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mortezaee, Keywan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 10.05.2021 Date Revised 10.05.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009619666191019143539 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303412984 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303412984 | ||
| 003 | DE-627 | ||
| 005 | 20231225112756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009619666191019143539 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1011.xml |
| 035 | |a (DE-627)NLM303412984 | ||
| 035 | |a (NLM)31738153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mortezaee, Keywan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2021 | ||
| 500 | |a Date Revised 10.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Cancer is one of the most complicated diseases in present-day medical science. Yearly, several studies suggest various strategies for preventing carcinogenesis. Furthermore, experiments for the treatment of cancer with low side effects are ongoing. Chemotherapy, targeted therapy, radiotherapy and immunotherapy are the most common non-invasive strategies for cancer treatment. One of the most challenging issues encountered with these modalities is low effectiveness, as well as normal tissue toxicity for chemo-radiation therapy. The use of some agents as adjuvants has been suggested to improve tumor responses and also alleviate normal tissue toxicity. Resveratrol, a natural flavonoid, has attracted a lot of attention for the management of both tumor and normal tissue responses to various modalities of cancer therapy. As an antioxidant and anti-inflammatory agent, in vitro and in vivo studies show that it is able to mitigate chemo-radiation toxicity in normal tissues. However, clinical studies to confirm the usage of resveratrol as a chemo-radioprotector are lacking. In addition, it can sensitize various types of cancer cells to both chemotherapy drugs and radiation. In recent years, some clinical studies suggested that resveratrol may have an effect on inducing cancer cell killing. Yet, clinical translation of resveratrol has not yielded desirable results for the combination of resveratrol with radiotherapy, targeted therapy or immunotherapy. In this paper, we review the potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Resveratrol | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a molecular targeted therapy | |
| 650 | 4 | |a neoplasm | |
| 650 | 4 | |a radiation | |
| 650 | 4 | |a radiotherapy | |
| 650 | 4 | |a tumor microenvironment. | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Radiation-Protective Agents |2 NLM | |
| 650 | 7 | |a Resveratrol |2 NLM | |
| 650 | 7 | |a Q369O8926L |2 NLM | |
| 700 | 1 | |a Najafi, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Farhood, Bagher |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Shabeeb, Dheyauldeen |e verfasserin |4 aut | |
| 700 | 1 | |a Musa, Ahmed E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 20(2020), 2 vom: 18., Seite 130-145 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:2 |g day:18 |g pages:130-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009619666191019143539 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 2 |b 18 |h 130-145 | ||